复方苦参注射液对原发性肝癌患者术后复发的预防作用及生存函数分析  

The prophylactic effect and survival function of compound kushen injection on postoperative recurrence of primary liver cancer

作　　者：郝春海 田立斌[1] 何津[1] HAO Chun-hai;TIAN Li-bin;HE Jin(hepatobiliary surgery department,people's Hospital of Tangshan(Tangshan hebei,063000)China)

机构地区：[1]唐山市人民医院肝胆外科,河北唐山063000

出　　处：《中西医结合肝病杂志》2020年第4期303-306,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：唐山市科技攻关项目:(No.2018335)。

摘　　要：目的:研究复方苦参注射液对原发性肝癌患者术后复发的预防作用及其生存时间函数分析。方法:选取本院2014年1月至2016年1月接受手术治疗的98例原发性肝癌患者,随机分为对照组与观察组,两组患者均在本院接受择期肝切除术,对照组患者于术后接受预防性肝动脉化疗栓塞术(TACE)治疗,观察组患者在对照组治疗基础上加用复方苦参注射液。术后3个月,对比两组患者临床疗效,并观察手术前后两组患者血清肿瘤标志物与免疫功能指标T细胞亚群的变化情况;随访不低于2年,统计两组患者6个月、1年、2年时的复发率,并以生存函数分析两组患者的无病情进展生存时间与总生存时间。结果:观察组患者临床控制率为95.92%,对照组为87.76%,观察组临床疗效较对照组理想(P<0.05);治疗后两组患者IFN-γ、TNF-α、TAP、AFP水平均较本组术前改善(P<0.05),且观察组患者各项指标水平均优于对照组(P<0.05);术后,观察组患者NK细胞、CD4^+、CD8^+、CD4^+/CD8^+均较术前改善(P<0.05),且均优于对照组同期,对照组患者CD4^+与CD8^+均较术前恶化P<0.05,NK细胞与CD4^+/CD8^+与术前比较无差异(P>0.05);观察组患者2年累积复发率为14.29%,对照组为32.65%,两者比较,(P<0.05);观察组患者PFS与OS均长于对照组,(P<0.05)。结论:复方苦参注射液能有效降低原发性肝癌患者术后的复发率,改善患者免疫功能、进一步降低肿瘤标志物的表达水平,延长患者无病情进展生存时间与总生存时间。objective:to study the preventive effect of compound kushen injection on postoperative recurrence of primary hepatocellular carcinoma.Methods:98 patients with primary liver cancer who received surgical treatment in our hospital from January 2014 to January 2016 were included in this study,they were included in the patients after randomly divided into control group and observation group respectively,two groups of patients in our hospital underwent elective liver resection,the control group in prophylactic hepatic artery embolism chemotherapy postoperatively with conventional treatment,the observation group in the control group treatment for compound injection of sophora injection therapy at the same time;3 months after surgery,the clinical efficacy of the two groups was compared,and the changes of serum tumor markers and t-cell subsets of immune function indicators in the two groups were observed.The follow-up was no less than 2 years,and the recurrence rate of patients in the two groups was calculated at 6 months,1 year and 2 years.The survival function was used to analyze the disease-free progression survival time and total survival time of patients in the two groups.Results:the clinical control rate of the observation group was 95.92%,and that of the control group was 87.76%.After treatment,the IFN-twist,TNF-α,TAP and AFP levels of patients in the two groups were all improved(P<0.05)compared with the preoperative levels of this group,and the levels of various markers in the observation group were all better than those in the control group(P<0.05).After surgery,NK cells,CD4^+,CD8^+,CD4^+/CD8^+in the observation group all improved(P<0.05)compared with the preoperative period,and were all better than the control group at the same time.The cumulative recurrence rate of the observation group for 2 years was 14.29%,and that of the control group was 32.65%.The postopera-tive recurrence rate of the observation group was lower than that of the control group(P<0.05).PFS and OS in the observation group were longer than t

关 键 词：原发性肝癌 术后复发 肝动脉化疗栓塞术 生存函数 

分 类 号：R735.7[医药卫生—肿瘤]